sourcing the best research evidence in ophthalmology

Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy (PLANET)

May 14, 2021

Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial.

Lee WK, Iida T, Ogura Y, Chen SJ, Wong TY, Mitchell P, Cheung GCM, Zhang Z, Leal S, Ishibashi T.

JAMA Ophthalmol. 2018 Jul 1;136(7):786-793.
Full text | Metrics.

Main finding: Improvement in visual and/or functional outcomes was achieved in more than 85% of participants who were treated with IAI monotherapy. The potential benefit of adding PDT could not be determined as fewer than 15% met the criteria of a suboptimal response to receive PDT.

Purpose: To evaluate intravitreal aflibercept injection (IAI) in PCV and compare IAI monotherapy with IAI plus rescue photodynamic therapy (PDT)
Study type: Randomized controlled trial
Condition: Polypoidal choroidal vasculopathy

Participants: ≥50yo, symptomatic macular PCV, BCVA 20/40-20/320 [6/12-6/96]